Schonfeld Strategic Advisors’s Vir Biotechnology VIR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$753K	Sell	73,914 -296,214	-80%	-$2.82M	﹤0.01%	1647
2026 Q1	$3.32M	Buy	+370,128	New	+$2.95M	0.02%	621
2025 Q2	–	Sell	-138,127	Closed	-$895K	–	2573
2025 Q1	$895K	Buy	+138,127	New	+$1.23M	0.01%	1335
2024 Q4	–	Sell	-52,276	Closed	-$392K	–	2417
2024 Q3	$392K	Sell	52,276 -223,485	-81%	-$1.94M	﹤0.01%	1537
2024 Q2	$2.45M	Buy	275,761 +253,395	+1,133%	+$2.43M	0.02%	820
2024 Q1	$227K	Buy	+22,366	New	+$228K	﹤0.01%	1745
2023 Q4	–	Sell	-162,128	Closed	-$1.52M	–	2249
2023 Q3	$1.52M	Buy	162,128 +138,387	+583%	+$1.97M	0.01%	897
2023 Q2	$582K	Buy	+23,741	New	+$596K	0.01%	1164
2023 Q1	–	Sell	-24,600	Closed	-$623K	–	2686
2022 Q4	$623K	Sell	24,600 -47,495	-66%	-$1.16M	0.01%	1408
2022 Q3	$1.39M	Buy	72,095 +9,795	+16%	+$249K	0.01%	1067
2022 Q2	$1.59M	Buy	62,300 +50,313	+420%	+$1.17M	0.02%	821
2022 Q1	$309K	Sell	11,987 -9,313	-44%	-$276K	﹤0.01%	1680
2021 Q4	$892K	Buy	+21,300	New	+$834K	0.01%	991

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Schonfeld Strategic Advisors's VIR Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its Vir Biotechnology (VIR) stake by 80% in Q2 2026, selling an estimated $2.82M and leaving 73,914 shares worth $753K. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

Schonfeld Strategic Advisors first reported a position in VIR in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.32M in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Schonfeld Strategic Advisors held 73,914 shares of Vir Biotechnology worth $753K as of Q2 2026.
Schonfeld Strategic Advisors sold 296,214 Vir Biotechnology shares in Q2 2026, an estimated $2.82M.
Vir Biotechnology made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1647 holding.
Schonfeld Strategic Advisors first reported a position in Vir Biotechnology in Q4 2021 and has held it in 13 quarters since.
Schonfeld Strategic Advisors's Vir Biotechnology position peaked at $3.32M in Q1 2026.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.